CACNA1C (CaV1.2) and other L-type calcium channels in the pathophysiology and treatment of psychiatric disorders: advances from functional genomics and pharmacoepidemiology
A role for voltage-gated calcium channels (VGCCs) in psychiatric disorders has long been postulated as part of a broader involvement of intracellular calcium signalling. However, the data were inconclusive and hard to interpret. We review three areas of research that have markedly advanced the field...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2022
|
| _version_ | 1797109861964578816 |
|---|---|
| author | Harrison, PJ Husain, SM Lee, H De Los Angeles, A Colbourne, L Mould, A Hall, NAL Haerty, W Tunbridge, EM |
| author_facet | Harrison, PJ Husain, SM Lee, H De Los Angeles, A Colbourne, L Mould, A Hall, NAL Haerty, W Tunbridge, EM |
| author_sort | Harrison, PJ |
| collection | OXFORD |
| description | A role for voltage-gated calcium channels (VGCCs) in psychiatric disorders has long been postulated as part of a broader involvement of intracellular calcium signalling. However, the data were inconclusive and hard to interpret. We review three areas of research that have markedly advanced the field. First, there is now robust genomic evidence that common variants in VGCC subunit genes, notably <i>CACNA1C</i> which encodes the L-type calcium channel (LTCC) Ca<sub>V</sub>1.2 subunit, are trans-diagnostically associated with psychiatric disorders including schizophrenia and bipolar disorder. Rare variants in these genes also contribute to the risk. Second, pharmacoepidemiological evidence supports the possibility that calcium channel blockers, which target LTCCs, might have beneficial effects on the onset or course of these disorders. This is especially true for calcium channel blockers that are brain penetrant. Third, long-range sequencing is revealing the repertoire of full-length LTCC transcript isoforms. Many novel and abundant <i>CACNA1C</i> isoforms have been identified in human and mouse brain, including some which are enriched compared to heart or aorta, and predicted to encode channels with differing functional and pharmacological properties. These isoforms may contribute to the molecular mechanisms of genetic association to psychiatric disorders. They may also enable development of therapeutic agents that can preferentially target brain LTCC isoforms and be of potential value for psychiatric indications. |
| first_indexed | 2024-03-07T07:47:14Z |
| format | Journal article |
| id | oxford-uuid:9e71c031-ba69-4ee9-a17e-abc714bfffa9 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:47:14Z |
| publishDate | 2022 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:9e71c031-ba69-4ee9-a17e-abc714bfffa92023-06-12T15:36:20ZCACNA1C (CaV1.2) and other L-type calcium channels in the pathophysiology and treatment of psychiatric disorders: advances from functional genomics and pharmacoepidemiologyJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:9e71c031-ba69-4ee9-a17e-abc714bfffa9EnglishSymplectic ElementsElsevier2022Harrison, PJHusain, SMLee, HDe Los Angeles, AColbourne, LMould, AHall, NALHaerty, WTunbridge, EMA role for voltage-gated calcium channels (VGCCs) in psychiatric disorders has long been postulated as part of a broader involvement of intracellular calcium signalling. However, the data were inconclusive and hard to interpret. We review three areas of research that have markedly advanced the field. First, there is now robust genomic evidence that common variants in VGCC subunit genes, notably <i>CACNA1C</i> which encodes the L-type calcium channel (LTCC) Ca<sub>V</sub>1.2 subunit, are trans-diagnostically associated with psychiatric disorders including schizophrenia and bipolar disorder. Rare variants in these genes also contribute to the risk. Second, pharmacoepidemiological evidence supports the possibility that calcium channel blockers, which target LTCCs, might have beneficial effects on the onset or course of these disorders. This is especially true for calcium channel blockers that are brain penetrant. Third, long-range sequencing is revealing the repertoire of full-length LTCC transcript isoforms. Many novel and abundant <i>CACNA1C</i> isoforms have been identified in human and mouse brain, including some which are enriched compared to heart or aorta, and predicted to encode channels with differing functional and pharmacological properties. These isoforms may contribute to the molecular mechanisms of genetic association to psychiatric disorders. They may also enable development of therapeutic agents that can preferentially target brain LTCC isoforms and be of potential value for psychiatric indications. |
| spellingShingle | Harrison, PJ Husain, SM Lee, H De Los Angeles, A Colbourne, L Mould, A Hall, NAL Haerty, W Tunbridge, EM CACNA1C (CaV1.2) and other L-type calcium channels in the pathophysiology and treatment of psychiatric disorders: advances from functional genomics and pharmacoepidemiology |
| title | CACNA1C (CaV1.2) and other L-type calcium channels in the pathophysiology and treatment of psychiatric disorders: advances from functional genomics and pharmacoepidemiology |
| title_full | CACNA1C (CaV1.2) and other L-type calcium channels in the pathophysiology and treatment of psychiatric disorders: advances from functional genomics and pharmacoepidemiology |
| title_fullStr | CACNA1C (CaV1.2) and other L-type calcium channels in the pathophysiology and treatment of psychiatric disorders: advances from functional genomics and pharmacoepidemiology |
| title_full_unstemmed | CACNA1C (CaV1.2) and other L-type calcium channels in the pathophysiology and treatment of psychiatric disorders: advances from functional genomics and pharmacoepidemiology |
| title_short | CACNA1C (CaV1.2) and other L-type calcium channels in the pathophysiology and treatment of psychiatric disorders: advances from functional genomics and pharmacoepidemiology |
| title_sort | cacna1c cav1 2 and other l type calcium channels in the pathophysiology and treatment of psychiatric disorders advances from functional genomics and pharmacoepidemiology |
| work_keys_str_mv | AT harrisonpj cacna1ccav12andotherltypecalciumchannelsinthepathophysiologyandtreatmentofpsychiatricdisordersadvancesfromfunctionalgenomicsandpharmacoepidemiology AT husainsm cacna1ccav12andotherltypecalciumchannelsinthepathophysiologyandtreatmentofpsychiatricdisordersadvancesfromfunctionalgenomicsandpharmacoepidemiology AT leeh cacna1ccav12andotherltypecalciumchannelsinthepathophysiologyandtreatmentofpsychiatricdisordersadvancesfromfunctionalgenomicsandpharmacoepidemiology AT delosangelesa cacna1ccav12andotherltypecalciumchannelsinthepathophysiologyandtreatmentofpsychiatricdisordersadvancesfromfunctionalgenomicsandpharmacoepidemiology AT colbournel cacna1ccav12andotherltypecalciumchannelsinthepathophysiologyandtreatmentofpsychiatricdisordersadvancesfromfunctionalgenomicsandpharmacoepidemiology AT moulda cacna1ccav12andotherltypecalciumchannelsinthepathophysiologyandtreatmentofpsychiatricdisordersadvancesfromfunctionalgenomicsandpharmacoepidemiology AT hallnal cacna1ccav12andotherltypecalciumchannelsinthepathophysiologyandtreatmentofpsychiatricdisordersadvancesfromfunctionalgenomicsandpharmacoepidemiology AT haertyw cacna1ccav12andotherltypecalciumchannelsinthepathophysiologyandtreatmentofpsychiatricdisordersadvancesfromfunctionalgenomicsandpharmacoepidemiology AT tunbridgeem cacna1ccav12andotherltypecalciumchannelsinthepathophysiologyandtreatmentofpsychiatricdisordersadvancesfromfunctionalgenomicsandpharmacoepidemiology |